BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 8834621)

  • 1. Humoral immunological response in patients with venom allergy during specific immunotherapy.
    Szymański W; Chyrek-Borowska S
    Rocz Akad Med Bialymst; 1995; 40(2):376-82. PubMed ID: 8834621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
    Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
    Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
    Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
    Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse reactions to venom immunotherapy.
    Ramirez DA; Londono S; Evans R
    Ann Allergy; 1981 Dec; 47(6):435-9. PubMed ID: 7325415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens.
    Carballada F; Boquete M; Núñez R; Lombardero M; de la Torre F
    J Investig Allergol Clin Immunol; 2010; 20(6):506-13. PubMed ID: 21243935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of specific IgE and IgG4 measurements in the follow-up of a hymenoptera venom immunotherapy treatment: apropos of 82 cases].
    Sonneville A; Loustanau O; Tahar HA; Menelet I
    Allerg Immunol (Paris); 2000 Jan; 32(1):20-5. PubMed ID: 10723532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy.
    Erdmann SM; Sachs B; Kwiecien R; Moll-Slodowy S; Sauer I; Merk HF
    Allergy; 2004 Oct; 59(10):1102-9. PubMed ID: 15355470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sequential analysis of specific IgE and IgG titres as a function of the cumulated doses of venoms injected in allergies to Hymenoptera and correlation with specific IgE, clinical manifestations and skin tests].
    Hutt N; Hutt-Kempf E; Thierry R; Pauli G; Guilloux L
    Allerg Immunol (Paris); 1988 Jan; 20(1):18-9, 22. PubMed ID: 3390295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new IgE specificities to hymenoptera allergens during venom-specific immunotherapy.
    Tavares B; Rordigues F; Pereira C; Loureiro G; Chieira C
    Eur Ann Allergy Clin Immunol; 2005 May; 37(5):171-6. PubMed ID: 15984315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and clinical relevance of specific immunoglobulin E to pollen caused by sting- induced specific immunoglobulin E to cross-reacting carbohydrate determinants in Hymenoptera venoms.
    Kochuyt AM; Van Hoeyveld EM; Stevens EA
    Clin Exp Allergy; 2005 Apr; 35(4):441-7. PubMed ID: 15836751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of Hymenoptera venom allergy in Eastern Spain.
    Fernandez J; Soriano V; Mayorga L; Mayor M
    Clin Exp Allergy; 2005 Feb; 35(2):179-85. PubMed ID: 15725189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical and biological surveillance after the cessation of Hymenoptera venom desensitization].
    Touraine F; Talayrach D; Florea O; Brianchon Ch; Preux PM; Bonnaud F
    Eur Ann Allergy Clin Immunol; 2003 Nov; 35(9):335-9. PubMed ID: 14716961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rush hyposensitization with Hymenoptera venoms. Tolerance and results of therapy].
    Przybilla B; Ring J; Griesshammer B; Braun-Falco O
    Dtsch Med Wochenschr; 1987 Mar; 112(11):416-24. PubMed ID: 3816590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term IgG4 determinations in hymenoptera-sensitive treated patients.
    Gentlesk MJ; Halpern GM; Mansmann HC
    Ann Allergy; 1987 Oct; 59(4):267-72. PubMed ID: 3662129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A; Yogev A; Confino-Cohen R
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
    Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
    Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.